The observation that targeting the 4-1BB pathway in cancer treatment ameliorates the elimination of tumor cells and prevents activation-induced cell death is in line with published data.35, 36 This advancement should be considered with respect to potential future in vivo use of gene-modified MSCs. The gene discussed is TNFRSF9; the disease is neoplasm.